

Globally recognized physician–scientist with 40+ years of leadership in neuroscience and regenerative medicine. He has authored 300+ peer-reviewed publications, holds over 100 global patents, and has led academic departments and clinical programs at leading institutions worldwide. His work focuses on translating advanced science into integrative, patient-centered care.

Entrepreneur and healthcare strategist advancing regenerative medicine through clinical delivery, education, and scalable care models. He is a founding member of the Institute for Regenerative Medicine & Neuroscience, founder of Wound Hubs, and creator of Reclaim Health Corp and Healora RX—platforms connecting patients and clinics to biologics, peptide therapies, and telehealth infrastructure.

Vice President and Director of the Institute of Regenerative Medicine & Neuroscience Foundation. With a background in advanced aesthetic wellness and hair restoration, she specializes in integrating innovative products and cutting-edge technologies to support hair health, natural beauty, and patient confidence. At IRMN, she leads the development of refined, patient-centered programs grounded in scientific rigor and individualized care.

MD, PhD, Professor of Addiction Medicine, Emeritus, University of Helsinki, Finland;
Specialist in Addiction Medicine; International Society for Addiction Medicine (ISAM)
Past President.
Professor Alho’s main interests are on pharmacological treatment of alcoholism,
prevention of alcohol related health problems, treatment of pathological gambling and
treatment opiate addictions. Professor Alho’s research team was one of the first to
demonstrate that targeted (as needed) opiate antagonist treatment naltrexone is effective
in reducing alcohol consumption and since has been active in the development and
testing of related treatments for AUD. He has been pioneering researcher of opioid
maintenance treatment in Finland and Scandinavia. Professor Alho has more than 230
original articles and several other publications and books on Teaching and Addiction
Medicine. Professor Alho continues actively his research, currently he is the
coordinating primary investigator of controlled clinical trial with psilocybin


Innovation
Fresh, creative solutions.

Integrity
Honesty and transparency.

Excellence
Top-notch services.
